ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/anti-VEGFR2-monoclonal-antibody
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/anti-VEGFR2-monoclonal-antibody
4
trial(s) found.
NCT07718737
Advanced
Phase 2 / Phase 3
Not yet recruiting
Open-Label, Global, Multicenter, Randomized, Phase 2/3 Study of AMT-116 Versus Investigator's Choice in Participants With Advanced or Metastatic Non-squamous EGFR-Wildtype Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy (
AMT-116-201
)
anti-CD44v9 antibody-drug conjugate
+ anti-VEGFR2 monoclonal antibody
NOT Squamous non-small-cell lung cancer
Non-small cell lung cancer
NSW
2109 - North Ryde - Macquarie University Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
NCT07546812
Advanced
Phase 2
Recruiting
A Phase 2, Open-Label, Multicenter, Randomized Study to Evaluate Denikitug as Monotherapy or in Combination With Nivolumab or Chemotherapy in Participants With HER2-Negative, Unresectable, Recurrent, and/or Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas (
GS-US-742-7757
)
anti-CCR8 monoclonal antibody
anti-PD-1 monoclonal antibody
+ anti-VEGFR2 monoclonal antibody
Gastric adenocarcinoma
Gastric cancer
Gastroesophageal junction adenocarcinoma
cytotoxic chemotherapy
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Hollywood Private Hospital
NCT07098338
Advanced
Phase 2
Recruiting
An Open-Label, Multi-Drug, Multi-Centre, Phase II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumour Activity of Novel Combinations in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (
LIBRA
)
Datopotamab Deruxtecan
Ramucirumab
Rilvegostomig
anti-Trop2 antibody-drug conjugate
anti-VEGFR2 monoclonal antibody
bispecific PD-1/TIGIT antibody
cancer therapy
cancer therapy,PD-1-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,TIGIT-targeting
cancer therapy,Trop2-targeting
cancer therapy,VEGFR2-targeting
immune checkpoint blockade
immune checkpoint blockade,PD-1-targeting
immune checkpoint blockade,TIGIT-targeting
immuno-oncology therapy,PD-1-targeting
immuno-oncology therapy,TIGIT-targeting
immuno-oncology therapy,Trop2-targeting
immuno-oncology therapy,VEGFR2-targeting
therapeutic modality,bispecific antibody
+ anti-VEGFR2 monoclonal antibody
Non-small cell lung cancer
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
SA
5011 - Woodville South - The Queen Elizabeth Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05999994
Paed
Phase 2
Recruiting
CAMPFIRE
: Children's and Young Adult Master Protocol for Innovative Pediatric Research
Abemaciclib
CDK4/6 inhibitor
CDK4 inhibitor
CDK6 inhibitor
Cyclophosphamide
Docetaxel
Gemcitabine
Irinotecan
Ramucirumab
Temozolomide
Vinorelbine
alkylating agent
anti-VEGFR2 monoclonal antibody
antimetabolite
cancer therapy
cancer therapy,CDK4-targeting
cancer therapy,CDK6-targeting
cancer therapy,VEGFR2-targeting
cytotoxic chemotherapy
immuno-oncology therapy,VEGFR2-targeting
taxane
topoisomerase inhibitor
vinca alkaloid
+ anti-VEGFR2 monoclonal antibody
Cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse (COMPLETED)
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre (COMPLETED)
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health (COMPLETED)
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (3)
Not yet recruiting (1)
Recruitment Country and State
NSW (2)
VIC (2)
SA (2)
WA (2)
QLD (1)
Phase
Phase 2 (3)
Phase 2 / Phase 3 (1)
Trial Type
Advanced (3)
Paed (1)
Cancer Therapy Class
VEGFR2
100%
PD-1
50%
PD-1/PD-L1
50%
CD44v9
25%
CCR8
25%
TIGIT
25%
Trop2
25%
CDK4
25%
CDK6
25%
Facility
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (2)
2050 - Camperdown - Chris O'Brien Lifehouse (2)
2109 - North Ryde - Macquarie University Hospital (1)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (1)
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute (1)
3065 - Fitzroy - St Vincent's Hospital Melbourne (1)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (1)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (1)
5042 - Bedford Park - Flinders Medical Centre (1)
6009 - Nedlands - Hollywood Private Hospital (1)
5011 - Woodville South - The Queen Elizabeth Hospital (1)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (1)
3000 - Melbourne - Peter MacCallum Cancer Centre (1)
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health (1)
Cancer Type
Cancer
Solid tumour
Thoracic cancer
Lung cancer
Non-small cell lung cancer
Respiratory tract cancer
Gastric adenocarcinoma
Gastric cancer
Gastric carcinoma
Gastroesophageal cancer
Gastroesophageal junction adenocarcinoma
Gastrointestinal cancer
Oesophageal cancer
Upper gastrointestinal cancer
cytotoxic chemotherapy
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy